New hope for tough cancers: experimental drug ITC-6146RO enters human testing
NCT ID NCT07423117
First seen Mar 01, 2026 · Last updated Apr 28, 2026 · Updated 10 times
Summary
This early-phase study tests a new drug called ITC-6146RO in about 100 adults with advanced or metastatic cancers (prostate, lung, breast, or other solid tumors) that have not responded to standard therapies. The goal is to find a safe dose and check for early signs of tumor shrinkage. Participants will receive the drug in escalating doses to determine the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.